The Alzheimer’s trial everyone’s sharing: What EVANTHEA really found
- Richard Moore
- Jan 13
- 9 min read
If you are living with Alzheimer’s disease (AD), mild cognitive impairment (MCI), or you are caring for someone who is, research headlines do not land like abstract science. They land like hope, pressure, and sometimes fear. A new study can feel like a lifeline. It can also feel like yet another promise that may not hold up.
That is why the recent EVANTHEA randomised controlled trial (RCT) preprint has created such a surge across clinician and health-innovation circles, including posts from James Maskell, Dr Kristine Burke, and Dr Dale Bredesen. The title is provocative: “Precision Medicine Treatment of Alzheimer’s Disease: Successful Randomized Controlled Trial.” (Toups et al., 2025).
In this blog, we will translate what the trial did and what it found, explain the statistics without diluting the science, and quietly do what good researchers do: hold both optimism and skepticism at the same time.
First, a small but important label: this is a preprint
The EVANTHEA paper is posted on Preprints.org and is clearly marked NOT PEER-REVIEWED (Toups et al., 2025).
Peer review is not a magic stamp that makes a study “true,” but it is a structured stress test. It often forces clarification of methods, strengthens analysis choices, and sometimes cools down overconfident interpretation. A preprint can still be high quality. It just means we should read it like an early cut of a film, not the final edit.
What is the Bredesen “Precision Medicine” idea, in human terms?
Traditional Alzheimer’s trials often test one main lever. Think of it like trying to fix a city-wide traffic problem by changing one traffic light.
Bredesen’s model treats Alzheimer’s more like a complex network problem: many small breakdowns can add up to cognitive symptoms. The “precision medicine” approach aims to measure multiple possible contributors in a given person and then target them in a structured way. That systems logic has been described in earlier Bredesen-linked academic work, starting with a small early report in Aging (Bredesen, 2014) and later proof-of-concept and rationale papers in Journal of Alzheimer’s Disease (Toups et al., 2022; Bredesen et al., 2023).
EVANTHEA matters because it attempts to test that idea under randomised conditions.
What EVANTHEA actually did
The trial enrolled 73 adults aged 45–76 with MCI or early dementia, requiring a Montreal Cognitive Assessment (MoCA) score of 18 or higher (Toups et al., 2025).
Participants were randomised 2:1 into two groups: 50 received a personalised “precision medicine” protocol, and 23 received standard of care, over nine months with repeated cognitive and symptom assessments (Toups et al., 2025).
The precision arm was built around broad testing for factors the authors link to cognitive decline, including inflammatory markers, insulin resistance and glycation, vascular risk, sleep-related hypoxemia, hormones, nutrients, toxin exposure, dysbiosis and infection signals, plus genetic and epigenetic measures and Alzheimer’s-associated biomarkers (Toups et al., 2025).
If that list feels overwhelming, that is because it is. Precision medicine is not a single “protocol.” It is a measurement-led way of building an individualized plan. The scientific question EVANTHEA asks is simple: does this structured, multi-factor approach outperform standard care in early-stage impairment?
The headline result, explained like you are not a statistician
One of the main cognitive measures was a computerised neuropsychological battery called CNS Vital Signs, which reports an overall score called the Neurocognitive Index (NCI) (Toups et al., 2025).
Here is the key detail that makes the numbers interpretable: the NCI is set so that 100 represents the 50th percentile (average), and the standard deviation (SD) is 15 (Toups et al., 2025).
If you are not used to “standard deviation,” think of it as the typical spread around average. On many standardised tests, about 15 points is roughly one noticeable step up or down from the middle.
In EVANTHEA, among participants who completed the study, the authors report:
The precision medicine group’s NCI increased from about 92 to 106, while the standard-of-care group decreased from about 97 to 92, with a between-group result reported as p < 0.001 (Toups et al., 2025).
That p-value is not a measure of how big the benefit is. It is a measure of how unlikely it would be to see a separation this large if there were truly no difference between the approaches. Put plainly, the groups diverged in a way that is unlikely to be random noise.
The paper also reports statistically significant incremental effects favouring the precision medicine group on composite memory, executive function, processing speed, and symptom severity measures (Toups et al., 2025).
Why some familiar scores did not “move,” and why that matters
Many patients and carers recognise the MoCA because it is used in clinics and memory services. In EVANTHEA, the MoCA did not show the same clear separation as the computerized testing, and the authors discuss the possibility of learning or “practice” effects on MoCA performance (Toups et al., 2025).
This is not a reason to dismiss the study, but it is a reason to be precise about what is and is not proven. Different cognitive tools have different sensitivity. Short screening tests can be less granular than multi-domain batteries, especially over months.
The authors argue that practice effects are less likely to explain the CNS Vital Signs changes because the tool is designed to reduce such effects and has published reliability and validity data (Toups et al., 2025; Gualtieri & Johnson, 2006).
Biomarkers and MRI: promising signals, not a full biological “receipt”
A fair question is: were these truly Alzheimer’s-pathway changes, or improvements in attention, sleep, and metabolic health that made test scores look better?
EVANTHEA includes Alzheimer’s-associated biomarkers. The authors report that many participants showed biomarker patterns consistent with Alzheimer’s pathophysiology and that phosphorylated tau at threonine 217 (p-tau217) showed a statistically significant incremental reduction in the precision medicine group relative to standard care, while several other markers did not show clear between-group differences (Toups et al., 2025).
On brain magnetic resonance imaging (MRI) volumetrics, the preprint reports no significant between-group differences in the measured volumes over the study period (Toups et al., 2025).
The honest interpretation is that the cognitive signal is stronger than the structural imaging signal across nine months, and the biomarker picture is suggestive but not yet a decisive mechanistic explanation.
The comparison everyone will ask about: how does this stack up to drug trials?
The authors state that the treatment effect size for overall cognitive function was larger than previously published monotherapy trials and they explicitly compare effect sizes to anti-amyloid antibody trials (Toups et al., 2025).
It is reasonable to be cautious here. Cross-trial effect size comparisons can be misleading because trials differ in outcome measures, eligibility criteria, follow-up length, and analysis choices. That said, it is also true that the major anti-amyloid RCTs have generally demonstrated slowing of decline rather than restoration of function, and they require monitoring for adverse events such as amyloid-related imaging abnormalities (ARIA) (van Dyck et al., 2023; Sims et al., 2023).
A constructive way to hold this is: EVANTHEA is not “proof that lifestyle beats drugs.” It is evidence that a multi-factor precision approach deserves serious scientific attention alongside pharmaceutical strategies.
A critical point that should not be whispered: complexity is part of the intervention
Even if EVANTHEA’s outcomes hold up, this is not a casual protocol. The preprint itself acknowledges that the approach can be demanding for patients and requires time from a practitioner team, and that cost and feasibility are real barriers that will need refinement (Toups et al., 2025).
This matters for carers reading this. If you have ever tried to implement sleep changes, nutrition changes, exercise, cognitive training, medication reviews, and multiple appointments while also managing daily life, you already know that “adherence” is not a personality trait. It is logistics, energy, money, time, and support.
Where EVANTHEA fits in the wider “multidomain” landscape
EVANTHEA is not the first multidomain brain-health trial. The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) trial showed that a structured multi-domain intervention can benefit cognition in at-risk older adults, providing important proof that multiple lifestyle levers can be studied rigorously (Ngandu et al., 2015).
More recently, Ornish and colleagues published an RCT in Alzheimer’s Research & Therapy testing intensive lifestyle changes in MCI or early dementia due to Alzheimer’s, again reinforcing that complex interventions can be trialed and can produce measurable changes across cognition and other outcomes (Ornish et al., 2024).
In that context, EVANTHEA is best seen as a specific version of a broader scientific movement: treating Alzheimer’s risk and early decline as partially modifiable through systems-level intervention, while still respecting that Alzheimer’s is a serious neurodegenerative disease, not a simple lifestyle problem.
What this means for patients and carers, in real life terms
If you take nothing else from this blog, take this: EVANTHEA does not say Alzheimer’s is easy to reverse. It suggests that in earlier stages, some people may experience meaningful cognitive improvement when multiple biological and lifestyle factors are assessed and addressed in a structured, personalised way (Toups et al., 2025).
That can be hopeful, but it can also be emotionally heavy. “If there is something we can do, are we doing enough?” That question can quietly exhaust families.
A healthier framing is: this research supports the idea that the brain is not a sealed unit. Sleep, cardiometabolic health, inflammation biology, nutrition status, physical activity, and cognitive engagement interact with brain function. Addressing them is not about blame. It is about support, resilience, and giving the brain the best possible operating conditions.
What this means for practitioners, including those using this approach in clinic
For practitioners, EVANTHEA raises both opportunity and responsibility.
The opportunity is that a randomised trial now exists for a precision medicine framework that has previously been supported mainly by case series and proof-of-concept work (Bredesen, 2014; Toups et al., 2022; Toups et al., 2025).
The responsibility is to communicate the evidence with discipline. This is a preprint. The comparator was standard of care, not an intensity-matched placebo protocol. MoCA did not separate clearly. MRI volumetrics did not separate over nine months. Those facts do not weaken the signal, but they define the boundaries of what can be claimed today (Toups et al., 2025).
In practical clinic terms, the study also underscores why training and team delivery matter. A complex, individualised protocol is only as good as the clinician’s ability to interpret data, prioritise interventions, monitor safety, coordinate with medical care, and reduce burden for patients and carers. In our clinic, we use this framework with trained support, including Nicolle as a practitioner, precisely because implementation needs to be structured and humane, not just technically “correct.”
The bottom line: hopeful, but not the finish line
EVANTHEA is a meaningful moment for Alzheimer’s research because it takes a controversial, widely discussed precision-medicine approach and tests it in a randomised design, reporting cognitive improvements in the intervention arm alongside health improvements and selected biomarker changes (Toups et al., 2025).
It is also not the final word. The next chapter needs peer review, independent replication, clearer identification of which components drive benefit, and careful work on feasibility and access so this does not become “science that only works for people with resources.”
For families reading this, it is reasonable to feel hope and still demand rigor. For practitioners reading this, it is reasonable to feel excitement and still practice restraint in claims. Both are acts of respect for the people living inside the diagnosis.
Meet Nicolle: Our ReCODE Practitioner who is supporting cognitive health
Nicolle, an RNTP and RN, is a Bredesen-trained in ReCODE who specialises in supporting adults with Alzheimer’s disease and other dementias, as well as those concerned about memory changes or reducing future risk. She brings over 20 years of experience as a memory clinic nurse and Alzheimer’s disease clinical trial nurse, and continues to work in research using the Clinical Dementia Rating (CDR) scale.
Nicolle offers a number of programmes that support cognitive health, including the PreCODE programme, which is Apollo's preventative health programme, and the ReCODE programme mentioned in this study, which is designed for those who have symptoms or a diagnosis of Alzheimer's Disease or other forms of dementia.
We also work closely with clients to develop bespoke programmes that support your specific diet, lifestyle and nutraceutical needs, and offer a wide range of tests, including nutrigenomic testing, metabolomic testing and standard blood tests.
To book a free initial call with Nicolle, email info@younutritionclinic.com.
🧩 Connect with us
For research updates, practical tips, and ongoing inspiration, follow us on Instagram:
Stay curious. Stay hopeful. Support your brain. 🧠
References
Bredesen, D. E. (2014). Reversal of cognitive decline: A novel therapeutic program. Aging (Albany NY), 6(9), 707–717. https://doi.org/10.18632/aging.100690
Bredesen, D. E., Toups, K., Hathaway, A., Gordon, D., Chung, H., Raji, C., Boyd, A., Hill, B. D., Hausman-Cohen, S., Attarha, M., Chwa, W. J., Kurakin, A., & Jarrett, M. (2023). Precision medicine approach to Alzheimer’s disease: Rationale and implications. Journal of Alzheimer’s Disease, 96(2), 429–437. https://doi.org/10.3233/JAD-230467
Gualtieri, C. T., & Johnson, L. G. (2006). Reliability and validity of a computerized neurocognitive test battery, CNS Vital Signs. Archives of Clinical Neuropsychology, 21(7), 623–643. https://doi.org/10.1016/j.acn.2006.05.007
Ngandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., … Kivipelto, M. (2015). A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): A randomised controlled trial. The Lancet, 385(9984), 2255–2263. https://doi.org/10.1016/S0140-6736(15)60461-5
Ornish, D., et al. (2024). Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer’s disease: A randomized, controlled clinical trial. Alzheimer’s Research & Therapy, 16, 82. https://doi.org/10.1186/s13195-024-01482-z
Sims, J. R., Zimmer, J. A., Evans, C. D., et al. (2023). Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA, 330(6), 512–527. https://doi.org/10.1001/jama.2023.13239
Toups, K., Hathaway, A., Gordon, D., Chung, H., Raji, C., Boyd, A., Hill, B. D., Hausman-Cohen, S., Attarha, M., Chwa, W. J., Jarrett, M., & Bredesen, D. E. (2022). Precision medicine approach to Alzheimer’s disease: Successful pilot project. Journal of Alzheimer’s Disease, 88(4), 1411–1421. https://doi.org/10.3233/JAD-215707
Toups, K., Tanio, C., Hathaway, A., Bergman, N., Burke, K., Haase, D., … Bredesen, D. E. (2025). Precision medicine treatment of Alzheimer’s disease: Successful randomized controlled trial (Preprint). Preprints.org. https://doi.org/10.20944/preprints202512.2694.v1
van Dyck, C. H., Swanson, C. J., Aisen, P., et al. (2023). Lecanemab in early Alzheimer’s disease. The New England Journal of Medicine, 388(1), 9–21. https://doi.org/10.1056/NEJMoa2212948
Comments